Temsirolimus, an mTOR-inhibitor, demonstrated prolonged activity in a patient with metastatic desmoplastic small round cell tumor.
Case Report (n=1)
Does temsirolimus provide prolonged activity in a patient with metastatic desmoplastic small round cell tumor?
Temsirolimus may offer prolonged activity in patients with metastatic desmoplastic small round cell tumor, a rare and aggressive neoplasm with poor prognosis.
Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive neoplasm that mostly occurs in young males. No curative treatment options currently exist for this type of tumor and long-term survival remains poor. In vitro rapamycin induces apoptotic death of JN-DSRCT-1 cells, a possible model for desmoplastic small round cell tumors in which the EWS gene is fused to the WT1 gene. We therefore demonstrate the prolonged activity of temsirolimus, an mTOR-inhibitor, in a patient with DSRCT.
Thijs et al. (Fri,) conducted a case report in Metastatic desmoplastic small round cell tumor (DSRCT) (n=1). Temsirolimus was evaluated on Prolonged activity. Temsirolimus, an mTOR-inhibitor, demonstrated prolonged activity in a patient with metastatic desmoplastic small round cell tumor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: